Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2025 | $263.00 | Outperform | RBC Capital Mkts |
| 10/24/2024 | $340.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Neutral | Redburn Atlantic | |
| 9/18/2024 | $379.00 | Outperform | Leerink Partners |
| 6/6/2024 | $370.00 | Buy | Goldman |
| 12/15/2023 | $357.00 | Buy | Truist |
| 9/13/2023 | $306.00 | Outperform | TD Cowen |
| 1/17/2023 | $215.00 → $260.00 | Equal Weight → Overweight | Barclays |
Highlights Net business wins in the quarter of $2,413 million; a net book to bill in the quarter of 1.18. Full year net business wins of $9,974 million; a net book to bill of 1.20. Closing backlog of $24.7 billion, an increase of 1.4% on quarter three 2024 and 8.3% on quarter four 2023. Quarter four revenue of $2,041.1 million, representing a decrease of 1.2% on prior year revenue. Full year revenue of $8,282 million representing a year on year increase of 2.0%. Quarter four adjusted EBITDA of $422.6 million or 20.7% of revenue, an increase of 0.9% on quarter three 2024. Full year adjusted EBITDA of $1,735.8 million or 21.0% of revenue, representing a year on year increase of 2.5%.
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 results after the market closes on Wednesday, February 19, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 20, 2025 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON
Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted share, an increase of 19.8% on quarter three 2023 diluted earnings per share. Quarter three adjusted net income was $279.2 million or $3.35 per diluted share, an increase of 1.5% on quarter three 2023 adjusted diluted earnings
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
RBC Capital Mkts initiated coverage of ICON plc with a rating of Outperform and set a new price target of $263.00
Robert W. Baird downgraded ICON plc from Outperform to Neutral and set a new price target of $340.00
Redburn Atlantic initiated coverage of ICON plc with a rating of Neutral
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025 at 8.00 am ET and at the Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025 at 8.30 am ET. Any changes to these events and links to the live webcasts will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to
BERWYN, Pa. and DUBLIN, March 4, 2025 /PRNewswire/ -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ:ICLR), a global healthcare intelligence and clinical research organization, today announce a partnership to utilize the participant management and payments platform, Mural Link. ICON will utilize Mural Link's innovative functionality related to clinical trial participant payments, tax management, travel and concierge support, site-participant communication tools, and novel reporting and analytics capabilities. "From our very first conversations with ICON, we were highly impressed by their commitment to patient care and innovation," s
Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes